• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail
-

FDA Broad Agency Announcement (BAA) or Program for Extramural Regulatory Science and Innovation (PERSI)

Description: PERSI encourages participation by science and technology based firms and educational institutions in meeting FDA goals for innovative ideas and approaches for regulatory science. PERSI-BAA identifies innovative and promising technologies for advanced development across the FDA which focuses on nine regulatory science research areas: (1) Modernize Toxicology to Enhance Safety; (2) Stimulate Innovation in Clinical Evaluation and Personalized Medicine to Improve Product Development and Patient Outcomes; (3) Support New Approaches to Improve Product Manufacturing and Quality; (4) Ensure FDA Readiness to Evaluate Innovative Emerging Technologies; (5) Harness Diverse Data Through Information Sciences to Improve Health Outcomes; (6) Enable a Prevention Focused Food Safety System; (7) Facilitate Development of Medical Countermeasures to Protect US and Global Health and Security; (8) Strengthen Social and Behavioral Science to Help Consumers and Professionals Make Informed Decisions; and (9) Strengthening the Global Product Safety Net. The BAA vehicle not only accelerates contract awards with flexible solicitation, but also reduces up-front planning and document reviews by creating unified advanced development solicitation. It provides flexibility to accommodate a range of contract awards (type, scope, number) in one vehicle which allows for market assessment of technologies. The BAA process starts with a quad chart/white paper review which will allow for a quick assessment of promising technologies from which to select full proposals. The second step includes establishing full review cycles of selected full proposals. After an extensive peer-review process, only a few proposals with the greatest importance to the FDA, are selected. PERSI-BAA is flexible and can be amended and modified anytime.

Accomplishment: The BAA program has sustained a consistent growth in the number of contract awards within FY14 and FY15. For example, FDA awarded 28 new projects in FY14 and 29 new projects in FY15. We completed 5 BAA projects in FY14 and 10 projects in FY15. Our FY16 awards are still in progress.

Briefing Status: ON TRACK

Prior Briefing Status: ON TRACK

Milestone DescriptionMilestone DateMilestone StatusMilestone Completion Date
A. Renew BAA 5/23/2014
Completed 5/23/2014
B. Complete FY14 3rd quarter full proposal reviews and monitor the progress of the executed awards 6/30/2014
Completed 8/28/2014
C. Complete FY14 4th quarter full proposal reviews and monitor the progress of the executed awards 9/30/2014
Completed 10/24/2014
D. Complete FY15 1st quarter full proposal reviews and monitor the progress of the executed awards 12/31/2014
Completed 1/28/2015
E. Complete FY15 2nd quarter full proposal reviews and monitor the progress of the executed awards 3/31/2015
Completed 3/31/2015
F. Complete FY15 3rd quarter full proposal reviews and monitor the progress of the executed awards 6/30/2015
Completed 6/30/2015
G. Complete FY15 4th quarter full proposal reviews and monitor the progress of the executed awards 9/30/2015
Completed 9/30/2015
H. Complete FY16 1st quarter full proposal reviews and monitor the progress of executed awards 12/30/2015
Completed 1/14/2016
I. Complete FY16 2nd quarter full proposal reviews and monitor the progress of executed awards 3/30/2016
Completed 5/30/2016
J. Complete FY16 3rd quarter full proposal reviews and monitor the progress of the executed awards 6/30/2016
Completed 7/1/2016
K. Complete FY16 4th quarter full proposal reviews and monitor the progress of the executed awards 9/30/2016
Completed 9/30/2016
L. Complete FY17 1st quarter full proposal reviews and monitor the progress of executed awards 12/30/2016
Completed 12/30/2016
M. Complete FY17 2nd quarter full proposal reviews and monitor the progress of executed awards 3/30/2017
Completed 3/21/2017
N. Complete FY17 3rd quarter full proposal reviews and monitor the progress of the executed awards 6/30/2017
Completed 6/30/2017
O. Complete FY17 4th quarter full proposal reviews and monitor the progress of the executed awards 9/30/2017
Completed 9/30/2017

Foot Notes

  • New milestones will be added for FY 2018.

Key Projects Legend

Milestone StatusDefinition
Not Yet StartedWork for specific milestone has not yet been started.
CompletedMilestone and/or overall project is completed.
On TrackMilestone - On track for completion by milestone deadline. Quarter status - Project is on track for completion based on overall milestone status.
On HoldMilestone - On hold, but deadline for completion has not passed. Quarter status - Project is on hold, based on overall milestone status.
DelayedMilestone - Delayed as it has not been completed and deadline has passed. Quarter status - Project is delayed based on overall milestone status.

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.

-
-